Initial clinical evidence on biperiden as antiepileptogenic after traumatic brain injury. A Randomized Clinical Trial

Maira Licia Foresti, Eliana Garzon, Mariana Teichner de Moraes, Rafael P Valeriano, Joao Paulo Santiago, Gustavo Mercenas dos Santos, Natalia Mata Longo, Carla Baise, Joaquina C Andrade, Maria Alice Susemihl, Maria da Graca Naffah Mazzacoratti, Wellingson Silva Paiva, Almir Ferreira Andrade, Manoel Jacobsen, Luiz E Mello
{"title":"Initial clinical evidence on biperiden as antiepileptogenic after traumatic brain injury. A Randomized Clinical Trial","authors":"Maira Licia Foresti, Eliana Garzon, Mariana Teichner de Moraes, Rafael P Valeriano, Joao Paulo Santiago, Gustavo Mercenas dos Santos, Natalia Mata Longo, Carla Baise, Joaquina C Andrade, Maria Alice Susemihl, Maria da Graca Naffah Mazzacoratti, Wellingson Silva Paiva, Almir Ferreira Andrade, Manoel Jacobsen, Luiz E Mello","doi":"10.1101/2023.11.10.23298341","DOIUrl":null,"url":null,"abstract":"There is currently no available drug to prevent the development of post-traumatic epilepsy. Preclinical studies support the potential use of anticholinergics. To evaluate whether treatment with biperiden has the potential to prevent post-traumatic epilepsy. Randomized, double-blind, placebo-controlled clinical trial, conducted between 2018- 2022. Adult patients with acute traumatic brain injury (TBI) following eligibility criteria were randomly assigned to placebo or biperiden groups. Biperiden or placebo was initiated within 12 h after trauma and repeated every 6 h for 10 days. Clinical evaluation was performed at 1, 3, 6, 12, 18, and 24 months after TBI to investigate seizures incidence. The primary outcome was a change in the incidence of post-traumatic epilepsy. Secondary outcomes included frequency of seizures, mortality and adverse events. Of 123 patients recruited, 1 declined and 1 was ineligible. After randomization, 11 (8.9%) participants were discontinued from the study. The mean (SD) age of the 112 remaining participants was 43.5 (17.6) years, and 19/112 (16.9%) were female. Of these, 27 (21.9%) participants died and 3 (2.4%) were lost in the follow-up. Of the remaining 82 (66.6%) participants, 61 (49.5%) completed the study. Data analysis indicated lack of evidence of biperiden for either, the incidence of post-traumatic epilepsy (2.6, 95%CI, 0.65-10.57; P = .170) or the mortality rate (1.57, 95%CI, 0.73-3.38; P=.248). Constipation (43.9%) was the most common adverse event observed. The frequency of late post-traumatic seizures was higher for biperiden group (2.03, 95%CI = 0.912-3.1597; p <0.001). There was insufficient evidence regarding the effect of biperiden in preventing post-traumatic epilepsy after TBI. The combined effect of variables known to have an impact on the likelihood of developing late post-traumatic seizures and its unbalanced frequency in the different groups is an aspect to be considered and underpins the need for larger studies.","PeriodicalId":478577,"journal":{"name":"medRxiv (Cold Spring Harbor Laboratory)","volume":"19 5","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv (Cold Spring Harbor Laboratory)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2023.11.10.23298341","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

There is currently no available drug to prevent the development of post-traumatic epilepsy. Preclinical studies support the potential use of anticholinergics. To evaluate whether treatment with biperiden has the potential to prevent post-traumatic epilepsy. Randomized, double-blind, placebo-controlled clinical trial, conducted between 2018- 2022. Adult patients with acute traumatic brain injury (TBI) following eligibility criteria were randomly assigned to placebo or biperiden groups. Biperiden or placebo was initiated within 12 h after trauma and repeated every 6 h for 10 days. Clinical evaluation was performed at 1, 3, 6, 12, 18, and 24 months after TBI to investigate seizures incidence. The primary outcome was a change in the incidence of post-traumatic epilepsy. Secondary outcomes included frequency of seizures, mortality and adverse events. Of 123 patients recruited, 1 declined and 1 was ineligible. After randomization, 11 (8.9%) participants were discontinued from the study. The mean (SD) age of the 112 remaining participants was 43.5 (17.6) years, and 19/112 (16.9%) were female. Of these, 27 (21.9%) participants died and 3 (2.4%) were lost in the follow-up. Of the remaining 82 (66.6%) participants, 61 (49.5%) completed the study. Data analysis indicated lack of evidence of biperiden for either, the incidence of post-traumatic epilepsy (2.6, 95%CI, 0.65-10.57; P = .170) or the mortality rate (1.57, 95%CI, 0.73-3.38; P=.248). Constipation (43.9%) was the most common adverse event observed. The frequency of late post-traumatic seizures was higher for biperiden group (2.03, 95%CI = 0.912-3.1597; p <0.001). There was insufficient evidence regarding the effect of biperiden in preventing post-traumatic epilepsy after TBI. The combined effect of variables known to have an impact on the likelihood of developing late post-traumatic seizures and its unbalanced frequency in the different groups is an aspect to be considered and underpins the need for larger studies.
创伤性脑损伤后双倍藤抗癫痫作用的初步临床证据。一项随机临床试验
目前还没有可用的药物来预防创伤后癫痫的发展。临床前研究支持抗胆碱能药物的潜在应用。目的:评价双苯醚治疗是否有预防创伤后癫痫的潜力。随机、双盲、安慰剂对照临床试验,于2018年至2022年进行。符合入选标准的成年急性创伤性脑损伤(TBI)患者被随机分配到安慰剂组或双哌啶组。双哌啶或安慰剂在创伤后12小时内开始,每6小时重复一次,持续10天。在脑外伤后1、3、6、12、18和24个月进行临床评估,以调查癫痫发作的发生率。主要结局是创伤后癫痫发病率的变化。次要结局包括癫痫发作频率、死亡率和不良事件。在招募的123例患者中,1例拒绝,1例不合格。随机分组后,11名(8.9%)受试者被终止研究。其余112名参与者的平均(SD)年龄为43.5(17.6)岁,其中19/112(16.9%)为女性。其中,27人(21.9%)死亡,3人(2.4%)在随访中失踪。在剩下的82名(66.6%)参与者中,61名(49.5%)完成了研究。数据分析显示,创伤后癫痫的发生率(2.6%,95%CI, 0.65-10.57;P = 0.170)或死亡率(1.57,95%CI, 0.73-3.38;P = .248)。便秘(43.9%)是最常见的不良反应。双哌啶组创伤后晚期癫痫发作频率较高(2.03,95%CI = 0.912-3.1597;p & lt; 0.001)。关于双柏登在预防创伤性脑外伤后癫痫中的作用,证据不足。已知影响晚期创伤后癫痫发作可能性的变量的综合效应及其在不同组中的不平衡频率是需要考虑的一个方面,并支持需要进行更大规模的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信